Oral L-arginine prevents murine coxsackievirus B3 myocarditis

Int J Cardiol. 2002 Dec;86(2-3):273-9. doi: 10.1016/s0167-5273(02)00279-6.

Abstract

We have previously demonstrated that administration of nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), aggravated murine coxsackievirus B3 myocarditis. In the present study, we evaluated the effects of L-arginine, a precursor of NO, upon acute and chronic myocarditis. Dietary L-arginine and L-arginine plus L-NAME (L-arginine+L-NAME group) were administered to coxsackievirus B3 (CB3)-infected C(3)H/He mice for 2 weeks (experiment I), and to CB3-infected mice from the second week until the fourth week after virus inoculation (experiment II). Infected control was prepared in each experiment. In experiment I, survival was higher in the L-arginine group compared with the other two groups, and cardiac damage was less. In addition, plasma concentrations of L-arginine and NO were elevated in the L-arginine group. In experiment II, cardiomyopathic lesion in the L-arginine group was less prominent associated with lower plasma catecholamine and lower myocardial collagen concentrations compared with the other two groups. Thus, L-arginine treatment may be effective not only in preventing the development of acute CB3 myocarditis but in ameliorating cardiac dysfunction in chronic myocarditis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Arginine / administration & dosage*
  • Arginine / therapeutic use*
  • Coxsackievirus Infections / complications*
  • Coxsackievirus Infections / mortality
  • Coxsackievirus Infections / prevention & control*
  • Disease Models, Animal
  • Enterovirus B, Human / drug effects*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C3H
  • Myocarditis / etiology*
  • Myocarditis / mortality
  • Myocarditis / prevention & control*
  • NG-Nitroarginine Methyl Ester / administration & dosage
  • NG-Nitroarginine Methyl Ester / therapeutic use
  • Severity of Illness Index
  • Survival Rate

Substances

  • Enzyme Inhibitors
  • Arginine
  • NG-Nitroarginine Methyl Ester